Bayer predicts that three of its drugs could reach over $1 billion in sales starting this year, helping rebuild its pipeline as its two top-selling drugs start to lose patent protection this year. The pharma giant is focusing on specialties such as cardiovascular, oncology, women's health, and cell and gene therapies . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge